D4S Stock Overview
Manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for D4S from our risk checks.
Daiichi Sankyo Company, Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥27.85 |
| 52 Week High | JP¥37.90 |
| 52 Week Low | JP¥23.85 |
| Beta | 0.26 |
| 11 Month Change | -7.17% |
| 3 Month Change | -23.24% |
| 1 Year Change | 13.30% |
| 33 Year Change | 20.51% |
| 5 Year Change | 41.61% |
| Change since IPO | 467.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| D4S | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 2.1% | -5.0% | -1.3% |
| 1Y | 13.3% | -22.0% | 7.4% |
Return vs Industry: D4S exceeded the German Pharmaceuticals industry which returned -21.6% over the past year.
Return vs Market: D4S exceeded the German Market which returned 7.1% over the past year.
Price Volatility
| D4S volatility | |
|---|---|
| D4S Average Weekly Movement | 5.3% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: D4S has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: D4S's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1899 | 18,726 | Sunao Manabe | www.daiichisankyo.com |
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with acute myeloid leukemia; and Injectafer, a ferric carboxymaltose injection to treat iron deficiency. It also provides Liziana and Savaysa, direct factor Xa inhibitors; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, and Sevikar HCT antihypertensive agents; Nilemdo, an oral treatment which lowers cholesterol; Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe to reduce cholesterol; and Efient, an anti-platelet agent.
Daiichi Sankyo Company, Limited Fundamentals Summary
| D4S fundamental statistics | |
|---|---|
| Market cap | €52.33b |
| Earnings (TTM) | €1.55b |
| Revenue (TTM) | €10.86b |
33.8x
P/E Ratio4.8x
P/S RatioIs D4S overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| D4S income statement (TTM) | |
|---|---|
| Revenue | JP¥1.76t |
| Cost of Revenue | JP¥419.99b |
| Gross Profit | JP¥1.34t |
| Other Expenses | JP¥1.09t |
| Earnings | JP¥250.40b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Jan 31, 2025
| Earnings per share (EPS) | 132.45 |
| Gross Margin | 76.11% |
| Net Profit Margin | 14.24% |
| Debt/Equity Ratio | 6.3% |
How did D4S perform over the long term?
See historical performance and comparisonDividends
1.3%
Current Dividend Yield46%
Payout RatioDoes D4S pay a reliable dividends?
See D4S dividend history and benchmarks| Daiichi Sankyo Company dividend dates | |
|---|---|
| Ex Dividend Date | Sep 27 2024 |
| Dividend Pay Date | Dec 10 2024 |
| Days until Ex dividend | 56 days |
| Days until Dividend pay date | 18 days |
Does D4S pay a reliable dividends?
See D4S dividend history and benchmarks